Edap TMS SA (EDAP)
2.45
-0.07
(-2.78%)
USD |
NASDAQ |
Nov 15, 16:00
2.46
+0.01
(+0.41%)
After-Hours: 20:00
Edap TMS Research and Development Expense (TTM): 8.741M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 8.741M |
| June 30, 2024 | 8.627M |
| March 31, 2024 | 8.219M |
| December 31, 2023 | 7.537M |
| September 30, 2023 | 6.502M |
| June 30, 2023 | 6.10M |
| March 31, 2023 | 5.522M |
| December 31, 2022 | 5.169M |
| September 30, 2022 | 4.477M |
| June 30, 2022 | 4.361M |
| March 31, 2022 | 4.225M |
| December 31, 2021 | 4.038M |
| September 30, 2021 | 5.109M |
| June 30, 2021 | 5.129M |
| March 31, 2021 | 5.034M |
| December 31, 2020 | 5.159M |
| September 30, 2020 | 4.379M |
| June 30, 2020 | 4.090M |
| March 31, 2020 | 4.177M |
| December 31, 2019 | 4.178M |
| September 30, 2019 | 3.636M |
| June 30, 2019 | 6.302M |
| March 31, 2019 | 6.626M |
| December 31, 2018 | 6.704M |
| September 30, 2018 | 7.604M |
| Date | Value |
|---|---|
| June 30, 2018 | 5.032M |
| March 31, 2018 | 4.667M |
| December 31, 2017 | 4.393M |
| September 30, 2017 | 4.324M |
| June 30, 2017 | 4.397M |
| March 31, 2017 | 4.333M |
| December 31, 2016 | 4.276M |
| September 30, 2016 | 3.670M |
| June 30, 2016 | 3.198M |
| March 31, 2016 | 3.013M |
| December 31, 2015 | 2.987M |
| September 30, 2015 | 3.118M |
| June 30, 2015 | 3.384M |
| March 31, 2015 | 3.846M |
| December 31, 2014 | 3.914M |
| September 30, 2014 | 3.940M |
| June 30, 2014 | 3.587M |
| March 31, 2014 | 3.152M |
| December 31, 2013 | 3.443M |
| September 30, 2013 | 3.540M |
| June 30, 2013 | 3.476M |
| March 31, 2013 | 3.729M |
| December 31, 2012 | 3.427M |
| September 30, 2012 | 3.350M |
| June 30, 2012 | 3.758M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.038M
Minimum
Dec 2021
8.741M
Maximum
Sep 2024
5.539M
Average
5.119M
Median
Research and Development Expense (TTM) Benchmarks
| DBV Technologies SA | 83.21M |
| Cellectis SA | 94.63M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | 143.17M |
| Akari Therapeutics PLC | 8.848M |